Explores telomere syndromes, telomerase expression, end replication problems, telomere length during aging, defects in telomerase genes, and mouse models.
Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.